News

Professor Stricker gave the keynote address to the International Society of Radiologists 2020 virtual conference Professor Stricker was honoured to be invited to give a keynote address on the role of MRI in prostate cancer. Professor Stricker has had a very active involvement in researching the role of MRI over the last decade. He has […]

Professor Stricker was the keynote speaker at the Australian Section of the World Society of Robotic Surgeons virtual conference recently. He was invited to talk on preserving sexual function after robotic surgery as well as the management of high-risk prostate cancer. Professor Stricker was part of an Asia Pacific Group of Experts discussing potency preservation

Professor Stricker and radiation oncologist Dr Jeremy De Leon head up the MR Linac care team at the GenesisCare specialist cancer centre. Professor Stricker stated that he was very impressed with the possibilities of this new device, the Elekta Unity. He explained that by combining MRI technology with radiation it would become possible to target

All these trials are all designed to improve the accuracy of treatment of prostate cancer particularly with the use of high quality MRI and PET scanning. Professor Stricker is Chief Investigator of these trials. Tom Cusick is helping to coordinate the trials and can be contacted on T.Cusick@garvan.org.au The MAGNIFI trial – This is a

Amila Siriwardana, one of Professor Stricker’s fellows, wins the 2019 BJUI Global Prize for the best paper between 1 July 2017 and 30 June 2018. This is a great honour for Dr Siriwardana and is a great credit to all the team working with Professor Stricker and Louise Emmett on the PSMA data. Many other

Recently European Urology Oncology accepted the publication of the largest focal NanoKnife therapy group in the world. The article: Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. Eur Urol Oncol (2019), https://doi.org/10.1016/j.euo.2019.04.008 looked at 123 patients all with MRI followup and biopsy followup with a minimum of one year follow up.

Professor Stricker was invited recently to present the outcomes of his focal therapy treatment with the NanoKnife at the international annual scientific meeting of the European Association of Urology.  Dr Blazevski, one of Prof Stricker’s fellows, presented the results of Stricker’s first 300 cases. The presentation of this data was well received. The same results

Professor Stricker is the first in New South Wales and the third in Australia to achieve this milestone.  He began the first robotic programme in New South Wales at St Vincent’s Private in 2006 and has performed almost half of all the cases at St Vincent’s campus. He has also mentored and taught many of

The 4th Friends of Israel Urological Symposium was held in early July in Tel-Aviv. Professor Stricker was an invited to present. Prof. Stricker’s presentation, “New approaches in potency preservation in RALP” was well received.

Prof Stricker was invited by Hadassah Urology Department to be the keynote speaker for their recent symposium on salvage treatments. In addition to teaching robotic surgery in theatre, he oversaw theatre setup for minimally invasive biopsies, established the MR fusion technology use and instructed the radiation oncology team on the use of brachytherapy. Prof Stricker